Eli Lilly Begins Clinical Trial for COVID-19 Therapies - COVID-19 Clinical Trial
Breaking News | COVID-19

Eli Lilly Begins Clinical Trial for COVID-19 Therapies

Eli Lilly and Co. reports it has begun clinical trials for testing therapies for COVID-19. The drug company said it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study baricitinib. The study will investigate baricitinib as a potential treatment for hospitalized patients diagnosed with COVID-19, beginning this month in the U.S. with a planned expansion to additional sites including Europe and Asia. Results are expected within the next two months. 

Long Island Doctors See Improvements with COVID-19 Patients 

Dr. Ryan Saadi, of Quantaira Health, partnered with Dr. Muhammad Alam and Dr. Imtiaz Ahmad at Plainview Hospital using the much-talked-about hydroxychloroquine combined with the antibiotic doxycycline. The combination therapy was administered to dozens of high-risk COVID-19 patients at three long term care facilities on Long Island. They say most of those patients have now fully recovered. 

Two Thirds of COVID-19 Patients Improve after Gilead Drug 

More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation. The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included — in one case because of a dosing error. 

Share this:

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.